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Molecular and Cellular Pathobiology
KR-POK Interacts with p53 and Represses Its Ability to
Activate Transcription of p21WAF1/CDKN1A
Bu-Nam Jeon1, Min-Kyeong Kim1, Won-Il Choi1, Dong-In Koh1, Sung-Yi Hong3, Kyung-Sup Kim1,
Minjung Kim2, Chae-Ok Yun2, Juyong Yoon4, Kang-Yell Choi4, Kyung-Ryul Lee5,
Kenneth P. Nephew6, and Man-Wook Hur1
Abstract
Transcriptional regulation by p53 is thought to play a role in its ability to suppress tumorigenesis. However,
there remain gaps in understanding about how p53 regulates transcription and how disrupting this function
may promote cancer. Here we report a role in these processes for the kidney cancer–related gene KR-POK
(ZBTB7C), a POZ domain and Kr€uppel-like zinc ﬁnger transcription factor that we found to physically interact
with p53. Murine embryonic ﬁbroblasts isolated from genetically deﬁcient mice (Kr-pok/ MEFs) exhibited
a proliferative defect relative to wild-type mouse embryonic ﬁbroblasts (MEF). The zinc ﬁnger domain of
Kr-pok interacted directly with the DNA binding and oligomerization domains of p53. This interaction was
essential for Kr-pok to bind the distal promoter region of the CDKN1A gene, an important p53 target
gene encoding the cell-cycle regulator p21WAF1, and to inhibit p53-mediated transcriptional activation
of CDKN1A. Kr-pok also interacted with the transcriptional corepressors NCoR and BCoR, acting to
repress histone H3 and H4 deacetylation at the proximal promoter region of the CDKN1A gene. Importantly,
Kr-pok/ MEFs displayed an enhancement in CDKN1A transactivation by p53 during the DNA damage
response, without any parallel changes in transcription of either the p53 or Kr-pok genes themselves.
Furthermore, Kr-pok promoted cell proliferation in vitro and in vivo, and its expression was increased in more
than 50% of the malignant human kidney cancer cases analyzed. Together, our ﬁndings deﬁne KR-POK as a
transcriptional repressor with a pro-oncogenic role that relies upon binding to p53 and inhibition of its
transactivation function. Cancer Res; 72(5); 1137–48. 2012 AACR.
Introduction
The BTB/POZ domain–containing proteins play various
cellular regulatory functions by interacting with proteins or by
controlling transcription through binding to target gene
promoters (1, 2). In particular, interactions between some of
the POK family proteins and coregulators (e.g., BCoR, NCoR,
SMRT, p300, and p120ctn) are major determinants in differ-
entiation, development, hematopoiesis, tumor suppression,
and oncogenesis (3–8). For example, promyelocytic leukemia
zinc ﬁnger (PLZF) controls the development of invariant
natural killer T-cell effector function and the maintenance
of spermatogonial stem cells. T-helper–inducing POK (Th-
POK, also known as cKrox) regulates the ratio of CD4 to CD8
cells through T-cell lineage commitment (9–12). Moreover,
the aberrant expression of POK family proteins such as B-cell
lymphoma 6 (BCL-6), FBI-1 (also called Pokemon), hyper-
methylated in cancer-1 (HIC-1), and PLZF fusion protein
(PLZF-RARalpha) have been implicated in cancers such as
lymphoma, spontaneous malignant tumors, and acute pro-
myelocytic leukemia (13–19). Recently, the functions of these
and other POK transcription factors have been characterized
by several research groups, including ours (20–25). However,
with the exception of the POK family proteins mentioned
above, the functions of many POK family proteins remain
uncharacterized, and the relationship between POK expres-
sion and their role in differentiation, development, tumor
suppression, and oncogenesis needs to be investigated (3).
The activation of cyclin/cyclin-dependent kinase (CDK)
complexes regulates cell proliferation through cell-cycle con-
trol (26). CDK inhibitors usually inhibit the activity of cyclin/
CDK complexes and regulate cell-cycle arrest (27). The CDK
inhibitor 1A (CDKN1A or p21) is a major player in cell-cycle
control and is a major transcriptional target of p53 (28, 29).
CDKN1A is mainly regulated at the transcriptional level by
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various oncogenes, tumor suppressors, and cellular regulators
and is regulated posttranslationally at the level of degradation
(30). The ability of p21 to inhibit proliferation may contribute
to its tumor suppressor function (26, 27), and a number of
oncogenes repressCDKN1A to promote cell growth and tumor-
igenesis (31). Whereas the induction of CDKN1A predominant-
ly leads to cell-cycle arrest in G1, G2, or S-phase, repression of
CDKN1A may have a variety of outcomes depending on the
cellular context (31, 32). p21 is a key component in cell-cycle
control and apoptosis that directs an antiapoptotic response
following DNA damage (33). p53-dependent regulation of p21
expression likely contributes to how p53 inﬂuences cell sur-
vival or death upon DNA damage (32–35).
The tumor suppressor p53 protects the integrity of the
genome. The inactivation of p53 plays a central role in tumor-
igenesis (36, 37). The p53 tetramer binds to its response
element, in which it can recruit various transcriptional cor-
egulators to regulate RNA polymerase II–mediated transcrip-
tion at p53 target gene promoters (36, 37). Normally, the p53
protein is short-lived and present at low levels. However, in
response to a variety of cellular stresses, p53 is stabilized and
activated via a phosphorylation and acetylation cascade (38).
Active p53 controls the expression of a set of genes required for
the induction of cell-cycle arrest, senescence, DNA repair, and
apoptosis (39–41). Regardless of the type of stress, the ﬁnal
outcome of p53 activation is either cell survival through cell-
cycle arrest and DNA repair or cell death, but the mechanism
leading to the choice between these outcomes has not yet been
elucidated (39–41).
We characterized the molecular and cellular functions of a
kidney cancer–related POK family transcription factor, KR-
POK, as a proto-oncoprotein that controls cell proliferation.
KR-POK is a potent negative regulator of CDKN1A, and the
molecular interaction between p53 and KR-POK is critical for
this regulation.
Materials and Methods
Plasmids, antibodies, and reagents
pcDNA3.0-FLAG-Kr-pok, pcDNA3.1-Kr-pok-Myc-His, and
pcDNA3.1-Kr-pokDPOZ constructs were prepared by cloning
cDNA fragments into pcDNA3.0 or pcDNA3.1 (Invitrogen).
GST-POZKr-pok and GST-ZFKr-pok proteins and cDNA fragments
encoding the POZ domain (a.a 1–132) and zinc ﬁngers (a.a 365–
468) were cloned into pGEX4T3 (Amersham Biosciences). All
plasmid constructs were veriﬁed by sequencing. Antibodies and
chemicals used are described in Supplementary Information.
Generation of Kr-pok/ knockout mice and MEF
preparation
Two sets of oligonucleotide primers (described in Supple-
mentary Information) were used to amplify a Kr-pok gene
NotI–XhoI DNA fragment (7.1 kb) and a BamHI–KpnI DNA
fragment (4.5 kb) by the PCR ampliﬁcation of mouse 129/SvJ
mouse J1 genomic DNA. We incorporated the long and short
arms into the targeting vector pPNT by ligation. The targeting
vector was designed to replace the entire exon 4 of the Kr-pok
gene (1,330 bp) with a positive selection marker, the PGK
promoter fusedwith a neomycin resistance gene. The targeting
vector was linearized by digestion with NotI and introduced
into 129/SvJmouse J1 embryonic stem cells by electroporation.
The ES cell clones resistant to G418 and ganciclovir were
selected and analyzed for homologous recombination by
Southern blotting. Two ES cell clones were injected into
C57BL/6J blastocysts. Kr-pok/ mice on a C57BL/6 genetic
background were generated by standard laboratory animal
procedures. Kr-pokþ/þ and Kr-pok/mouse embryonic ﬁbro-
blasts (MEF) were prepared by standard protocol.
Cell cultures, stable cell lines, and animals
Cells were cultured in themedia recommended byAmerican
Type Culture Collection. Stable NIH/3T3 cells overexpressing
Kr-pok were prepared by infection with a recombinant lenti-
virus (LentiM1.4-Kr-pok taggedwithHis andMyc) and selected
with puromycin.
For the in vivo tumor study, female nude mice (BALB/c-nu,
6–7 weeks of age) were kept in a laminar air ﬂow cabinet
maintained at 24 2C with 40% to 70% humidity under a 12-
hour light/dark cycle and speciﬁc pathogen-free conditions. All
facilities were approved by the Association for Assessment and
Accreditation of Laboratory Animal Care, and all animal
experiments were conducted in accordance with the institu-
tional guidelines of the Animal Core Facility of the Yonsei
University School of Medicine (Seoul, Korea).
Fluorescence-activated cell sorting analysis
Cells were ﬁxed with 70% ethanol and washed with PBS
containing 1% horse serum, and cellular DNAwas stained with
propidium iodide (100 mg/mL). A cell-cycle proﬁle and forward
scatter were determined using a Becton Dickinson FACSCa-
libur, and the data were analyzed using ModFit LT 2.0 (Verity
Software House, Inc.).
BrdUrd incorporation
Cells were grown in Dulbecco's modiﬁed Eagle's medium
(DMEM) containing 0.02 mmol/L of bromodeoxyuridine
(BrdUrd) for 12 hours, ﬁxed in 3.7% formaldehyde, incubated
with anti-BrdUrd monoclonal antibody, and ﬁnally incubated
with goat anti-mouse Cy2-conjugated secondary antibody.
Cells were soaked in a 40,6-diamidino-2-phenylindole (DAPI)
solution and mounted for photography with a Radiance 2000
multi-photon (MP) imaging system (Bio-Rad).
MTT assays
To investigate the effect of Kr-pok on cellular proliferation,
cells were plated onto 24-well dishes at 30% to 50% conﬂuency
and incubated. The cell growth of each sample was determined
by measuring the conversion of the tetrazolium salt MTT to
formazan.
GST-fusion protein puriﬁcation, in vitro transcription,
and translation of corepressors or p53 and pull-down
assays
Recombinant GST, GST-POZKr-pok, and GST-ZFKr-pok
fusion proteins were prepared from E. coli BL21 (DE3) by
glutathione-agarose 4 bead afﬁnity chromatography (Peptron).
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Corepressor and p53 polypeptides were prepared using TNT
extracts in the presence of [35S]-methionine (Promega). GST-
fusion protein–agarose bead complexes were incubated with
in vitro translated [35S]-methionine–labeled corepressors or
p53 polypeptides at 4C for 4 hours in HEMG buffer. The
reaction mixtures were centrifuged, pellets were rinsed, and
the bound proteins were separated using 12% SDS-PAGE. The
gels were exposed to X-ray ﬁlm (Kodak).
Immunoprecipitation assays
Cellswerewashed, pelleted, and resuspended in a lysis buffer
supplemented with protease inhibitors. The cell lysate was
precleared, and the supernatant was incubated overnight with
antibodies at 4C, followed by incubation with protein A/G
agarose beads. Beads were collected, washed, and resuspended
in equal volumes of 5 SDS loading buffer. Immunoprecipi-
tated proteins were separated with 12% SDS-PAGE. AWestern
blot analysis was done according to standard protocols.
Chromatin immunoprecipitation assays
Cells were ﬁxed with formaldehyde (ﬁnal 1%) to cross-link
Kr-pok, p53, and histones onto the CDKN1A promoter. The
remaining chromatin immunoprecipitation (ChIP) procedures
have been reported elsewhere (21). Oligonucleotide primer sets
used in ChIP are described in Supplementary Information.
Preparation of recombinant adenovirus overexpressing
Kr-pok and shRNA against Kr-pok mRNA
The Kr-pok cDNA was cloned into the adenovirus E1 shuttle
vector pCA14 (Microbix) to generate pCA14-Kr-pok. To prepare
recombinant adenovirus expressing short hairpin RNA (shRNA)
against Kr-pok, annealed shRNA DNA sequences [sense: 50-
GATCCCTCCAGTGCATCGTGAATGTTTTTCAAGAGA(loop)-
ACATTCACGATGCACTGGATTTTTTTGGAA(loop)-A-30, anti-
sense: 50-AGCTTTTCCAAAAA(loop)-AATCCAGTGCATCGTG-
AATGTTCTCTTGAA(loop)-AAACATTCACGATGCACTGGAG-
G-30) were cloned intopSilencer 2.0-U6 (Ambion) and subcloned
into the pDE1sp1A vector. The remaining procedures have been
described elsewhere and also in Supplementary Information
(21).
Analysis of Kr-pok action on tumor growth in vivo in a
xenograft assay
U343 tumor cells were implanted under the abdominal
skin of female BALB/c-nu mice. Once tumors reached 100 to
120 mm3 in volume, mice were injected intratumorally 3
times at 2-day intervals with either control dl324 or dl324-
Kr-pok adenovirus (1  109 PFU). For the dl324-shKr-pok
virus injections, viruses (2  108 PFU) were injected 5 times
with 2-day intervals. To the study the synergistic antitumor
effect of dl324-shKr-pok virus injection and g-irradiation
treatment, viruses (2  108 PFU) were injected 3 times at 2-
day intervals, and mice were treated with 5 Gy g-irradiation
2 days later (Gamma Cell 3000; Nordion Inc.). Tumor growth
was monitored by measuring the length and width of the
tumor 3 times a week using a caliper. Tumor volume was
calculated as 0.523Lw2, in which L is the length and w is the
width in mm.
Histology and immunohistochemistry
Histologic analyses of mice were conducted by following
standard protocols. The 4-mm formalin-ﬁxed, parafﬁn-embed-
ded tissue sections were stained with hematoxylin and eosin
reagent for counterstaining. 3,30-Diaminobenzidine immuno-
histochemical staining was done according to the manufac-
turer's instructions (R.T.U. VECTASTAIN ABC Kit; Vector
Laboratories, Inc.) after incubation with primary antibody.
Statistical analysis
Student t test was used for the statistical analyses.
Results
Kr-pok promotes cell proliferation
KR-POK, which is encoded by the ZBTB7C gene, contains
a POZ domain (a.a. 8–132) and 4 Kr€uppel-like zinc ﬁngers
(a.a. 365–468). Murine KR-POK (Kr-pok) is primarily located
in the nucleus and is expressed ubiquitously in mouse
tissues (Supplementary Fig. S2). To study the function
of the Kr-pok protein, we generated Kr-pok knockout mice
by homologous recombination of mouse embryonic stem
cells (Fig. 1A). The targeting vector was designed to replace
the entire exon 4 of the Kr-pok gene with a positive selection
marker, the PGK promoter fused with a neomycin resistance
gene.
To investigate the effect of Kr-pok on cell proliferation, a ﬂow
cytometry [ﬂuorescence-activated cell sorting (FACS)] analysis
of Kr-pokþ/þ MEF and Kr-pok/ MEF cells was done. The
analyses revealed that the proportion of cells in the S-phase
decreased from35.2% to 20.1%with a loss of Kr-pok. InNIH/3T3
cells, Kr-pok increased the number of cells in the S-phase from
23.7% to46.6%, and thenumber of cells inG2-Mphasedecreased
from 23.1% to 2.7% with the ectopic expression of Kr-pok
(Fig. 1B). MTT assays Kr-pokþ/þ MEF, Kr-pok/ MEF, and
NIH/3T3 cells showed that Kr-pok promotes cell proliferation.
Furthermore, BrdUrd incorporation assays indicated that
Kr-pok promotes a transition from the G0–G1 to S-phase,
indicating the proliferative effect of Kr-pok (Fig. 1C and D).
Kr-pok represses CDKN1A gene expression
Because Kr-pok has a signiﬁcant effect on cell proliferation,
we investigated whether Kr-pok regulates the expression of
genes important in the cell cycle such as CDKN1A, which
encodes p21. Transient cotransfection of the Kr-pok expres-
sion vector and the promoter Luciferase fusion constructs
into HEK293 cells followed by transcription assays revealed
that Kr-pok repressed the transcription of both the ARF and
CDKN1A genes by 65% and 50%, respectively (Fig. 2A). p21
expression in Kr-pok/ MEF cells was higher than that of
Kr-pokþ/þ MEF cells at both the mRNA and protein levels.
NIH/3T3 cells with ectopic expression of Kr-pok had lower
p21 expression levels (Fig. 2B and C).
Transcriptional repression of the CDKN1A promoter by
Kr-pok involves inhibition of p53 activity in
transcription
Mapping of the upstream cis-regulatory element of the
CDKN1A promoter that is responsible for transcriptional
Transcriptional Repression of CDKN1A by KR-POK
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repression by Kr-pok showed that Kr-pok most potently
repressed the transcription of the promoter with a 2.3-kb
upstream sequence containing the distal p53 binding element
(Fig. 3A). In p53-null MB352 cells cotransfected with pGL2-
CDKN1A-Luc (-2.3 kb) and the Kr-pok expression vector,
ectopic p53 potently activated the transcription of CDKN1A,
an effect that was signiﬁcantly inhibited by Kr-pok (Supple-
mentary Fig. S3A). In HEK293 cells (wild-type p53) treated
with the DNA-damaging agent etoposide, CDKN1A transcrip-
tion was activated by induced p53, which was repressed by
Kr-pok (Supplementary Fig. S3B). Transient cotransfection and
transcription assays with pGL2-TP53 promoter-Luc and Kr-pok
expression plasmids of the same cells, revealed that Kr-pok
did not affect the transcription of the p53 gene (Supplementary
Fig. S3C).
Furthermore, we investigated whether ectopic Kr-pok
expression could repress endogenous CDKN1A gene expres-
sion in HCT116 p53þ/þ and p53/ cells. Kr-pok repressed
transcription in HCT116 p53þ/þ cells but only very weakly in
HCT116 p53/ cells, suggesting that Kr-pok inhibits
Figure 1. Kr-pok promotes cell proliferation. A, gene targeting approach to produce Kr-pok/ mice by homologous recombination of mouse embryonic
stem cells and genotyping of Kr-pok/ mice by PCR. B, FACS analysis of Kr-pok/ MEF cells and stable NIH/3T3-Kr-pok cells. C, MTT assay of cell
proliferation. Kr-pokþ/þ and Kr-pok/ MEF cells were cultured for 0 to 6 days, and analyzed for the MTT-to-formazan conversion by colorimetry at 540 to
600 nm. Alternatively, NIH3T3 and stable NIH/3T3-Kr-pok cell were grown 0 to 6 days and analyzed as above. D, BrdUrd incorporation assay. NIH/3T3
and NIH/3T3-Kr-pok cells were grown in DMEM containing BrdUrd. The cells were ﬁxed, incubated with anti-BrdUrd antibody, and soaked with DAPI.
Cells with incorporated BrdUrd were counted.
Jeon et al.
Cancer Res; 72(5) March 1, 2012 Cancer Research1140
on July 31, 2013. © 2012 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst January 17, 2012; DOI: 10.1158/0008-5472.CAN-11-2433 
endogenous p53 activity, which is important in the transcrip-
tion of CDKN1A (Supplementary Fig. S3D).
Kr-pok interacts with p53, and the complex binds to the
distal p53 binding element
Because Kr-pok inhibits the transcriptional activation
of CDKN1A by p53, we investigated whether Kr-pok inter-
acts with p53. Coimmunoprecipitation of total Kr-pokþ/þ
MEF and Kr-pok/ MEF cell lysates using anti–Kr-pok
antibody and GST-fusion protein pull-down assays showed
that p53 and Kr-pok interacted with each other directly
by an interaction between the GST-ZFKr-pok and the DNA
binding oligomerization domain of p53 (Fig. 3B; Supple-
mentary Fig. S4A and S4B). We next investigated whether
Kr-pok binds to the CDKN1A promoter and the functional
signiﬁcance of the protein interaction between Kr-pok
and p53 by ChIP assays. In p53 wild-type HEK293 cells,
Kr-pok speciﬁcally binds to the distal p53 binding region
(bp 2,307 to 1,947) but not to other regions tested
(Fig. 3C and D).
We also investigated whether Kr-pok interacts with the p53
mutants (p53Mt) that are found frequently in human cancers
and whether the in vivo binding requires the wild-type con-
formation of the DBD of p53. Kr-pok interacts with the p53Mt
withmutations at the DNA binding domain or oligomerization
domain (R175H, G245S, R248W, R273H, and K320R; Supple-
mentary Fig. S4C and S4D). However, ChIP assays revealed
that p53 with mutations in the DNA binding domain neither
bind to the p53 binding element nor recruit Kr-pok. In
contrast, p53K320R, which has a mutation in the oligomeri-
zation domain (a.a. 320), but retains DNA binding capability,
recruited Kr-pok to the distal p53 binding element in vivo
(Fig. 3D). The conformation of the p53 DNA binding domain
and actual binding of p53 seems to be important in Kr-pok
binding. These data indicate that Kr-pok can be tethered to the
CDKN1A distal promoter region by directly interacting with
p53 using its zinc-ﬁnger domain to repress the transcription of
the CDKN1A.
We investigated whether the protein interaction between
p53 and Kr-pok in transcriptional repression is limited to the
Figure 2. Kr-pok repressesCDKN1Agene expression. A, transient transcription assays. Theplasmid expressingKr-pok and reporter plasmidswere transiently
cotransfected into HEK293 cells, and luciferase activity was measured. Shown left are the schematic structures of reporter plasmids. B, RT-PCR analysis of
p21mRNA isolated from theKr-pokþ/þandKr-pok/MEFcells. Also examined is thep21mRNA in theNIH/3T3andstableNIH/3T3-Kr-pokcells infectedwith
recombinant lentivirus. C, Western blot analysis of p21 expression in the Kr-pokþ/þ MEF, Kr-pok/ MEF, NIH/3T3, and NIH/3T3-Kr-pok cells. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; WB, Western blot.
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regulation of CDKN1A or whether the interaction is also
signiﬁcant in the other genes that are controlled by p53.
Quantitative reverse transcriptase PCR (qRT-PCR) and West-
ern blot analyses showed that Bax, Noxa, and Survivin expres-
sion was derepressed in Kr-pok/ MEF cells but that Kr-pok
has no effect on the Puma gene (Supplementary Fig. S5A
and S5B). Interestingly, the antiapoptotic Survivin was dere-
pressed in Kr-pok/ MEF cells even though this gene is
repressed by p53. p53 and Kr-pok may interact to repress
the transcription of the Bax, Noxa, and Survivin gene pro-
moters by a mechanism similar to that for CDKN1A. Although
Survivin expression is increased in Kr-pok/ MEF cells, cells
still undergo cell-cycle arrest or apoptosis, probably because
Kr-pok regulates other genes that are important in cell cycle
or apoptosis.
KR-pok represses the transcriptional activation of the
CDKN1A promoter via g-irradiation–induced p53
Because Kr-pok represses CDKN1A gene transcription,
we examined whether Kr-pok and g-irradiation affect the
expression of p53 and p21 in Kr-pokþ/þ MEF and Kr-pok/
MEF cells. Endogenous p21 mRNA levels were higher in
Kr-pok/ MEF cells compared with that of Kr-pokþ/þ MEF
cells, suggesting a repressive role of Kr-pok on endogenous
CDKN1A gene transcription. Kr-pok mRNA expression in
Kr-pokþ/þ MEF cells was not altered by g-irradiation. p53
mRNA expression induced by g-irradiation was similar
regardless of Kr-pok genetic backgrounds. g-Irradiation
increased the transcription of the CDKN1A gene 2.6-fold
in Kr-pok/ MEF cells and 2-fold in Kr-pokþ/þ MEF cells,
suggesting an inhibitory role of endogenous Kr-pok on
Figure 3. Kr-pok interacts with p53 and the complex binds to the distal p53 binding element. Kr-pok directly interacts with p53 via its zinc ﬁngers. A,
transient transcription assays. Plasmids expressing Kr-pok and the pGL2-CDKN1A-Luc fusion promoter constructs were transiently cotransfected
into HEK293 cells and analyzed for luciferase activity. B, coimmunoprecipitation of endogenous Kr-pok and p53. Lysates prepared from the Kr-pokþ/þ
and Kr-pok/ MEF cells were immunoprecipitated using the anti-Kr-pok antibody and analyzed using Western blotting with anti-p53 antibody.
C, structures of human CDKN1A gene promoter. Arrows at the promoter regions indicate the locations of ChIP PCR primer sets. D, left: ChIP assay of
Kr-pok binding to the endogenous CDKN1A promoter in HEK293 cells. Cells were transfected with pcDNA3.0-FLAG-Kr-pok, and chromatin was
immunoprecipitated with the antibodies indicated. Arrows indicate the primers used in ChIP. Right: ChIP assay of Kr-pok binding to the endogenous
CDKN1A promoter in HCT116 p53/ cells. HCT116 p53/ cells were transfected with FLAG-Kr-pok and/or p53 wild-type and mutant expression
plasmids and immunoprecipitated with the antibodies indicated. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IP, immunoprecipitation;
WB, Western blot.
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p53-dependent CDKN1A gene transcription. The Western
blot analysis of p21 protein expression in Kr-pokþ/þ MEF
and Kr-pok/ MEF cell lysates showed similar results to
the p21 mRNA analysis (Fig. 4A and C). The role of Kr-pok
as a transcriptional repressor in response to DNA damage
is also supported by a gain-of-function study in NIH/3T3
cells. g-Irradiation increased CDKN1A gene transcription
6-fold in the NIH/3T3 cells, but the transcriptional acti-
vation was signiﬁcantly decreased by ectopic Kr-pok and
was increased only 2-fold by g-irradiation. Kr-pok does
not affect p53 gene transcription. The Western blot ana-
lysis of p21 protein expression in NIH/3T3 cell lysates
showed similar results to the p21 mRNA analysis (Fig. 4B
and D).
Kr-pok interacts with transcriptional corepressors to
repress transcription and deacetylate histones H3 and
H4 at the proximal promoter via its POZ domain
Kr-pok binds to the p53 binding element with p53, and
Kr-pok, thereby inhibits the transcriptional activation of
CDKN1A by p53. Mutant Kr-pokDPOZ, which lacks the POZ
domain, did not inhibit transcription, suggesting that the
POZ domain is important in transcriptional repression
(Fig. 5A). Transcriptional repressors often inhibit transcrip-
tion through an interaction with corepressors such as SMRT,
NCoR, and BCoR. Mammalian 2-hybrid assays using
pG5-Luc, pGal4-POZ, and pVP16-corepressor fusion expres-
sion plasmids have previously shown that the POZ domain
interacts with NCoR and BCoR but not with SMRT (4, 7, 8).
Our studies showed that the POZ domain strongly interacts
with NCoR (Supplementary Fig. S6A). Corepressor com-
plexes recruited by transcriptional repressors often contain
histone deacetylase (HDAC) proteins. We found that the
HDAC inhibitor TSA signiﬁcantly decreased transcriptional
repression by Kr-pok. This ﬁnding suggests a role for HDACs
in transcriptional repression by Kr-pok (Supplementary
Fig. S6B).
GST-fusion protein pull-down assays also showed that the
POZ domain directly interactedwith NCoR and BCoR (Fig. 5B).
Coimmunoprecipitation of Kr-pokþ/þ and Kr-pok/MEF cell
extracts showed that Kr-pok interacts with NCoR and HDAC3
(Fig. 5C; Supplementary Fig. S6C). The ChIP assay showed that
Kr-pok decreased the amount of acetylated histonesH3 andH4
at the proximal promoter (Fig. 5D). These data suggest that
histone deacetylation at the CDKN1A gene proximal promoter
is responsible for transcriptional repression by the p53–Kr-
Figure 4. Kr-pok represses
transcriptional activation of the
CDKN1A promoter by g-irradiation–
induced p53. A, qRT-PCR analysis of
p21 mRNA from Kr-pokþ/þ and
Kr-pok/ MEF cells exposed to
g-irradiation. B, qRT-PCR analysis of
p21 mRNA from NIH/3T3 and stable
NIH/3T3-Kr-pok cells exposed to
g-irradiation. C, Western blot
analysis of p21 expression from
Kr-pokþ/þ and Kr-pok/ MEF cells
exposed to g-irradiation. D, Western
blot analysis of p21 expression from
NIH/3T3 and stable NIH/3T3-Kr-pok
cells exposed to g-irradiation.
GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; WB,
Western blot.
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pok-corepressor–HDAC3 complex on the distal p53-respon-
sive element.
Kr-pok promotes tumor growth in a mouse xenograft
model
The adenovirus Ad-dl324-Kr-pok, overexpressing Kr-pok,
promoted the tumor growth after infecting of U343 MG tumor
cells implanted under the skin of female nude mice (BALB/c-
nu). U343 cells express p53WT and KR-POK, and form tumors
easily. By day 60 of infection, tumors infected with Ad-dl324-
Kr-pok reached an average volume of 1,190.5 mm3, but those
treated with Ad-dl324 (control) reached only 390.4 mm3.
Alternatively, the knockdown of Kr-pok expression by an
infection with sh-Kr-pok adenovirus inhibited tumor growth
by 71% (Fig. 6A,n¼ 6,P< 0.05). Finally, to study the feasibility of
knocking down KR-POK to treat cancer, we examined whether
the recombinant adenovirus, Ad-dl324-shKr-pok, plus g-irra-
diation could signiﬁcantly reduce tumor size. U343 MG tumor
cells were implanted under the skin of female BALB/c-numice,
recombinant Ad-dl324-shKr-pok, or control Ad-dl324 was
injected into the tumor, and subsequently tumors were
exposed to g-irradiation (5 Gy). Whereas either Ad-dl324-
shKr-pok or g-irradiation alone reduced the tumor volume,
the 2 agents combined induced potent and synergistic tumor
volume reduction (Fig. 6B, n ¼ 6, P < 0.05).
KR-POK expression is high in human kidney cancer
tissues
An immunohistochemical analysis of human tissue
microarrays of paired normal and cancer tissues using an
antibody against KR-POK showed that KR-POK expression
was signiﬁcantly higher in kidney, cervix, parotid gland, soft
tissue, and thymus cancer tissues compared with paired
normal tissues (Fig. 7A and B). In particular, KR-POK
expression was signiﬁcantly higher than normal in 47 of
69 (68.1%) malignant kidney cancer cases tested, but in
the other 22 malignant cases, the percentage of KR-POK–
positive cells was similar to that of normal kidney tissues.
The mean percentage of KR-POK–positive cells in normal
kidney tissues was 1.71%, and that of malignant kidney
Figure 5. Kr-pok interacts with
transcriptional corepressors to
repress transcription and
deacetylate histones H3 and H4 at
the proximal promoter via its POZ
domain. A, the pGL2-CDKN1A-Luc
and expression vector of Kr-pok or
Kr-pokDPOZ were transiently
cotransfected into HEK293 cells,
and luciferase activities were
measured. B, GST-fusion protein
pull-down assays. Recombinant
GST or GST-POZ was incubated
with in vitro synthesized [35S]-
methionine–labeled corepressors,
pulled down, and resolved by
12% SDS-PAGE. The gel was
exposed to X-ray ﬁlm. C,
coimmunoprecipitation of
endogenous Kr-pok, NCoR,
SMRT, and HDAC3. Lysates
prepared from the Kr-pokþ/þ
and Kr-pok/ MEF cells were
immunoprecipitated with the
anti-Kr-pok antibody and analyzed
by Western blotting with the
antibodies indicated. D, ChIP
assays of the proximal promoter of
endogenous p21 using antibodies
against acetylated H3 and H4.
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cancer tissues with high KR-POK expression was 10.1%
(P < 0.05), suggesting a high correlation between KR-
POK expression and kidney cancer development (Fig. 7A,
P < 0.05). Accordingly, we refer to this kidney cancer–related
POK family transcription factor as KR-POK. High KR-POK
expression in cancer tissue seems to increase tumor growth
by stimulating cancer cell proliferation.
Discussion
POK family proteins with a BTB/POZ domain and a
Kr€uppel-like zinc ﬁnger are major regulators of differenti-
ation, development, hematopoiesis, oncogenesis, and tumor
suppression (3–8). We characterized the biochemical and
cellular functions of a proto-oncogenic POK family tran-
scription factor, KR-POK, the expression of which is high in
kidney cancer tissues [47 of 69 (68%) malignant kidney
cancer patients]. This high expression suggests that a strong
correlation exists between KR-POK expression level and
kidney cancer development. Our investigation revealed that
Kr-pok represses the transcription of ARF and the cell-cycle
arrest gene CDKN1A. And p53-responsive CDKN1A gene is
the direct target gene of Kr-pok. The transcriptional repres-
sion of ARF can down regulate p53 expression, and Kr-pok
inhibits the transcriptional activity of p53, which results in
the repression of CDKN1A gene expression. These data may
explain why Kr-pok potently stimulates cell proliferation
and tumor growth.
Our mechanistic study on the transcriptional repression
of CDKN1A by Kr-pok provides information on the func-
tions of protein interactions between Kr-pok, p53, and
corepressors in CDKN1A gene transcription and perhaps in
cell proliferation. From on our ﬁndings, we propose a
hypothetical model of the transcriptional regulation of the
CDKN1A gene by Kr-pok (Supplementary Fig. S7). In the
absence of or with low levels of Kr-pok, when p53 expression
is at basal levels or is induced by DNA damage, the tran-
scription of the CDKN1A gene is activated by p53 and
coactivator interaction, which acetylates histones at the
proximal promoter. In cancer cells with high Kr-pok expres-
sion such as kidney cancer tissues, Kr-pok and p53 complex
binding to the distal p53-responsive element represses tran-
scription of the CDKN1A gene. The recruitment of a core-
pressor complex to the Kr-pok–p53 complex at the distal
promoter results in the deacetylation of histones at the
proximal promoter of CDKN1A (Supplementary Fig. S7). The
conformation of the p53 DNA binding domain and actual
binding of p53 seems to be important in Kr-pok binding
and transcriptional repression by the p53 and Kr-pok com-
plex. In addition, we found that the function of protein
interaction between p53 and Kr-pok in transcriptional
repression is not limited to CDKN1A but that the interaction
Figure 6. Kr-pok promotes tumor
growth in a mouse xenograft model.
A, tumor xenograft assay with brain
glioma U343 cells. The tumor tissues
were injected with the indicated
recombinant adenoviruses, and
tumor volume was measured every 2
days. Mice were injected with the
control adenovirus dl324, dl324/Kr-
pok, or dl324-shKr-pok. B, xenograft
assay of tumor (brain glioma U343
cell derived) growth after combined
treatment with g-irradiation and
adenovirus dl324-shKr-pok. The
tumor tissues were injected with the
control adenovirus dl324 or dl324-
shKr-pok and subsequently exposed
to g-irradiation (5 Gy). Tumor volume
was measured every other day.
Tumor volumes are indicated as the
mean  SEM. , P < 0.05 versus
control dl324.
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is also signiﬁcant in the regulation of other genes that are
reported to be controlled by p53, including Bax, Noxa, and
Survivin, but not Puma.
KR-POK (APM-1, ZBTB7C) was originally isolated as an
aberrant fusion transcript with papillomavirus oncogenes in
cervical carcinoma cell lines. APM-1 was shown to inhibit foci
formation in HeLa and CaSki cells and was proposed to be a
tumor suppressor (42). However, our thorough investigation of
the function of KR-POK in Kr-pokþ/þ, Kr-pok/ MEF, NIH/
3T3, and HEK293 cells reveals that KR-POK is in fact a proto-
oncoprotein candidate.
The tumor suppressor p53 is a DNA damage inducible
transcriptional activator of CDKN1A, and it plays a crucial
role in growth arrest, DNA repair, and apoptosis. Our
data show that Kr-pok inhibits the transcriptional activa-
tion of CDKN1A by interacting with p53 and thereby
inhibits cell-cycle arrest under DNA damage or normal
physiologic conditions. p53 is an important transcriptio-
nal activator of many genes that regulate cell cycle,
apoptosis, metabolism, development, differentiation, and
forth. Moreover, p53 was found to act as a transcriptional
repressor of many genes, such as dUTPase, Cdc20, and
Pdk1, by an interaction with corepressors and other reg-
ulatory proteins (43–45). In particular, protein interac-
tions among p53, mSin3A, and HDAC1 were found to be
important in the regulation of Map4 and stathmin gene
expression. In other studies, p53 was found to interact
with HDAC and Polycomb on the promoter of the tumor
suppressor Arf (46). Kr-pok contains sequences for speciﬁc
transcription factor features and acts as a transcriptional
corepressor to recruit NCoR-HDAC complexes (47). In
this respect, it is similar to FBI-1, which acts as an AR
corepressor by recruiting NCoR and SMRT in prostate
cancer cells (48).
Recently, our group published a paper on the regulation of
the CDKN1A gene by MIZ-1 and Kr-pok at the proximal
promoter region, where binding competition between MIZ-1
and Kr-pok is important. We were able to show novel actions
of MIZ-1 and Kr-pok and the potential involvement of p53
and Sp1 in the process. Although we were able to dissect the
molecular mechanism in great detail at the proximal pro-
moter, the molecular events on the distal p53 binding
elements were unknown. This article describes the molec-
ular events of the protein interaction between p53 and
Kr-pok on the distal p53 binding element, and we attempted
to illustrate the functional signiﬁcance of this unique protein
interaction. p53 stimulates cell proliferation by interacting
with Kr-pok, and this interaction is potentially important
in oncogenesis or proliferation of cancer cells with high p53
and Kr-pok expression.
Figure 7. KR-POK expression is
high in human kidney cancer
tissues. A, immunohistochemical
analysis of KR-POK expression in
paired normal (N) and cancerous (C)
kidney tissues. The microscopy
images were analyzed by the
ImmunoRatio Program (http://
imtmicroscope.uta.ﬁ/immunoratio;
, P < 0.05; , No statistical
signiﬁcance, t test).^, percentage
of KR-POK–positive cells in each
normal and tumor kidney tissue;
—, mean percentage of total KR-
POK–positive cells (%). B,
immunohistochemistry of paired
normal and cancer tissues of the
cervix, parotid gland, thymus, and
soft tissues. The KR-POK
expression was analyzed as above,
revealing that KR-POK levels are
high in these cancer tissues.
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Our ﬁndings on p53 and KR-POK have clinical implica-
tions that are relevant to genotoxic ionizing radiation ther-
apy or chemotherapy. Many cancer treatment strate-
gies, such as ionizing radiation and chemotherapy, take
advantage of the p53 functions of inducing cell-cycle arrest
and apoptosis in response to severe DNA damage. Our study
suggests that for cancer tissue expressing a high level of
KR-POK, additional therapeutic methods that can reduce
KR-POK expression may be needed for successful cancer
treatment.
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